All In Biotech

Drug Trial Radar · NCT06592326

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination With Toripalimab Versus Standard Chemotherapy in First-line Locally Advanced or Metastatic Urothelial Cancer

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

460

Planned (sponsor's estimate)

Start

Aug 22, 2024

Primary completion

Sep 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of 9MW2821 combined with Toripalimab versus standard chemotherapy in first-line locally advanced or metastatic urothelial cancer.

Conditions

  • Urothelial Carcinoma

Interventions

  • 9MW2821Drug

    9MW2821, 1.25mg/kg, intravenous (IV) infusion

  • ToripalimabDrug

    Toripalimab, 240mg, intravenous (IV) infusion

  • GemcitabineDrug

    Gemcitabine: 1000mg/m2, intravenous (IV) infusion

  • Cisplatin/CarboplatinDrug

    Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BICR-PFSTime frame: up to 50 months
  2. OSTime frame: up to 50 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.